Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 425.05
-0.65 (-0.15%)
At close: Jul 31, 2026
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 162.61 billion as of July 31, 2026. Its market cap has decreased by -57.38% in one year.
Market Cap
162.61B
Enterprise Value
164.58B
Revenue
22.69B
Ranking
n/a
PE Ratio
90.73
Stock Price
425.05
ChartMarket Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 162.61B, an increase of 482,351.16%. That is a compound annual growth rate of 276.52%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 31, 2026 | 162.61B | -19.59% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| J. B. Chemicals & Pharmaceuticals | 387.31B |
| Rubicon Research | 247.16B |
| Granules India | 206.66B |
| AstraZeneca Pharma India | 202.25B |
| Caplin Point Laboratories | 192.62B |
| Jubilant Pharmova | 152.25B |
| CORONA Remedies | 127.89B |
| Viyash Scientific | 109.95B |